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Should Everolimus-Eluting
Stents Be Preferred in
Patients With Acute and
Stable Coronary Syndromes?*
Sanjay Kaul, MD, George A. Diamond, MD
Los Angeles, California
Drug-eluting stents (DES) were first approved in the
United States in 2003 on the basis of improvement in
angiographic and clinical restenosis. The first 2 DES, now
referred to as “first-generation” DES, were the sirolimus-
eluting stent (SES) (Cypher, Cordis Corporation, Miami
Lakes, Florida; approved in 2003) and paclitaxel-eluting
stent (PES) (Taxus, Boston Scientific, Natick, Massachu-
setts; approved in 2004). Within a few months of approval,
early signs began to accumulate suggesting that DES were
associated with increased risk of sub-acute stent throm-
bosis and adverse cardiac outcomes. This was followed by
indications that the benefits of DES relative to restenosis
and target-lesion revascularization (TLR) might have been
See page 1104
overestimated and risks relative to stent thrombosis (ST)
might have been underestimated in preapproval randomized
controlled trials conducted primarily in relatively low-risk
patients and lesions, compared with more complex patients
and lesions treated in clinical practice (the so-called “off-
label use”) (1). Nonetheless, the DES use continued un-
abated, peaking at nearly 92% of all percutaneous coronary
interventions (PCIs) in 2006. Eventually, 2 highly publi-
cized study-level meta-analyses presented at the European
Society of Cardiology (ESC) Congress in 2006 (2,3) ignited
a firestorm of controversy. As a result, the U.S. Food and
Drug Administration Circulatory System Devices Advisory
Panel advised against “off-label” use of DES and recom-
mended extending dual antiplatelet therapy (DAPT) to at
least 12 months to mitigate the risk of late ST (4).
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contents of this paper to disclose.In 2008, the newer “second-generation” DES, zotarolimus-
eluting stent (Endeavor, Medtronic CardioVascular, Santa
Rosa, California) and the everolimus-eluting stent (EES)
(Xience V, Abbott Vascular, Santa Clara, California), were
approved for use on the basis of noninferiority to PES in
populations very similar to those in the initial SES and PES
trials. Although the drugs and polymer coatings of the
first-generation DES are considered biocompatible, they are
associated with allergic reactions and chronic inflammation
of the vessel wall, which might cause impaired re-
endothelialization and delayed healing leading to slight
excess of late ST and higher incidence of remodeling
resulting in malapposition, attenuation of antirestenotic
efficacy (the so-called “catch-up” phenomenon), and coro-
nary artery aneurysm formation late after device implanta-
tion. The newer DES have a stent platform of a cobalt-
chromium alloy and are thinner and more flexible than the
first-generation DES, thereby rendering them more deliv-
erable. Another advantage is improved biocompatibility
resulting in less inflammatory response and more rapid
vessel endothelialization or healing. The second-generation
DES have quickly replaced SES and PES in most centers,
on the basis of the results of the randomized trials and
registry experience. Consequently, EES is presently the
most commonly used stent in the United States and Europe.
In this issue of JACC: Cardiovascular Interventions, Planer
et al. (5) pooled together the individual patient data from 4
prospective randomized trials that compared EES with PES
in patients with coronary disease and focused on the
comparative efficacy and safety in patients with acute coro-
nary syndromes (ACS) over 2 years of follow-up. The
principal finding in the current report is that, compared
with PES, the use of EES resulted in superior safety and
efficacy in both ACS and stable coronary artery disease,
exhibiting substantial reductions in myocardial infarction
(MI), ST, and ischemia-driven TLR with no significant
difference in total or cardiac mortality. The study provides
the best available data, short of a dedicated prospective
randomized trial, on outcomes involving the most widely
used DES in complex patients presenting with ACS in
whom the majority of PCIs are performed in the United
States (6).
There are several strengths and limitations of the present
dataset that merit consideration. First, with more than
13,000 patient-years of follow-up, including the availability
of a large number of ACS patients (2,381 patients), the
present pooled analysis is 1 of the largest randomized
comparisons between any 2 DES and clearly the largest in
patients with ACS.
Second, the availability of individual patient data allows
more informative analyses such as the time-to-event and
covariate-adjusted analyses leading to more reliable and
valid treatment estimates than is possible with trial-level
aggregate data.
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1117Third, poolability across the 4 trials was justified by use of
common endpoint definitions and absence of statistical
heterogeneity. Although a purist might yet argue that these
trials nevertheless manifest a substantial amount of residual
clinical heterogeneity, important hypothesis-generating in-
sights can be gained by pooling.
Fourth, although pooled results were stratified by clinical
presentation (ACS vs. stable coronary artery disease), ran-
domization was not similarly stratified in any of the 4 trials,
thereby challenging the interpretability of these data. Strat-
ification can be used to avoid imbalances in prognostic
factors, thereby decreasing the chance of a type I error
(finding a difference between treatment arms because of
chance alone), type II error (not finding a difference if 1
exists), and increasing the validity of subgroup analyses (7).
That similar results were obtained with or without covariate
adjustment provides reassurance that imbalances in prog-
nostic covariates did not have a material impact on out-
comes. Nonetheless, stratified randomization, as was done
for assessment of treatment effect in diabetes in 3 of the 4
trials by the same investigators (8), would have yielded more
reliable and valid treatment estimates.
Fifth, a 2-year follow-up cannot be considered long
enough to fully evaluate the potential of very late ST and
“delayed” restenosis observed with first-generation DES.
The erosion of the early advantage of SES compared with
PES in TLR did not emerge until 5 years of follow-up (9).
Indeed, in the SPIRIT II (A Clinical Evaluation of the
Xience V Everolimus Eluting Coronary Stent System in the
Treatment of Patients with de novo Native Coronary Artery
Lesions) trial, the superiority of EES detected at 6 months
vanished at 2 years, as demonstrated by late angiographic
and intravascular ultrasound catch-up phenomenon (10),
suggesting this phenomenon is not unique to first-
generation DES. Whether these effects might have a larger
impact in more complex lesions than evaluated in the
SPIRIT II trial also remains unclear. In addition, although
the risk of ST is much lower with EES compared with PES,
without comparative data against bare-metal stents (BMS),
it is not possible to know that the 2-year rates observed in
non–ST-segment elevation myocardial infarction (1.6%)
and ST-segment elevation myocardial infarction (1.3%)
cohorts are reassuringly low. Longer follow-up is required to
better define the risk of late ST and consequently the
optimal duration of DAPT required to mitigate this risk.
Fortunately, a 5-year follow-up is planned for all 4 trials that
will help clarify these issues.
Sixth, it can be argued that the superiority of EES was
only demonstrated because it was compared with PES,
which historically is regarded as less efficacious and safer
than SES. Indeed, a formal meta-analysis of 5 randomized
trials including 7,370 patients showed no difference with
regard to ST and statistically comparable need for reinter-
vention between EES and SES (11). The surprising deci-sion by Cordis/Johnson & Johnson to abandon manufacture
of SES after 2011 has important implications with regard to
the choice of the best benchmark against which future-
generation DES should ideally be evaluated.
Seventh, in addition to reporting the results of the
conventional endpoint that combines safety and efficacy
outcomes (target vessel failure or major adverse cardiac
event), the authors also report data for the clinically relevant
composite endpoint of cardiac death, MI, or ST. Ideally,
endpoints such as TLR and MI that do not lie on the same
pathophysiologic spectrum should not be combined (12).
Finally, data regarding DAPT at and beyond 1 year are
not reported. It is unclear whether differences in duration of
DAPT were included in the Cox model used for covariate
adjustment. Therefore, to what extent these differences
contribute to outcomes cannot be discerned.
The clinical implications of the present study require
careful consideration. Should the data be taken to imply that
EES is the preferred DES, especially in patients with ACS,
given that the zotarolimus-eluting stent has not been shown
to be superior to PES and that SES will no longer be
available in the near future? The value of EES has been
established by comparisons with PES. Without data from
randomized trials comparing EES with current-generation
BMS, can we reliably recommend EES as the default choice
for PCI in all patients with ACS? Previous trials in acute
MI suggest that PES offers modest efficacy advantage over
BMS in reducing TLR without reducing ST, MI, or death
(13). The American College of Cardiology/American Heart
Association guideline recommendations indicate that DES
are a reasonable alternative (Class IIa, Level of Evidence: B)
to BMS in ST-segment elevation myocardial infarction
patients at low risk for bleeding, who are likely to be
compliant with DAPT and who do not have any planned
imminent surgery (14)—all very difficult to assess during the
emergency setting of an acute MI. Although, the current
results allay the concerns of ST with EES in ACS, the
modest albeit statistically significant benefit in clinical
restenosis coupled with the increased cost of EES and the
attendant prolonged DAPT argues against EES being the
default stent choice for PCI in all patients with ACS. A
DES, preferably EES, might be considered for clinical and
anatomic settings in which the efficacy/safety/cost profile
seems favorable as shown below:
Mitigate risk at “acceptable” benefit: avoid DES in
patients unable or unlikely to take DAPT or in need
of noncardiac procedures; extend antiplatelet therapy
beyond 12 months (perhaps indefinitely in patients at
low bleeding risk)
Accentuate benefit at “acceptable” risk: judicious,
selective, evidence-based use ideally reserved for pa-
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1118tients at highest risk for restenosis (longer lesions30
mm, smaller vessels 3.0 mm, insulin-treated diabetes)
Recently, a temporal reduction in DES use from an
nrestricted use in 92% of all PCIs in the years 2004 to 2006
o a more selective 68% use in 2007 was reported to be
ssociated with a small 1% increase in TLR without any
ncrease in repeat revascularization, death, or MI and a
odest reduction in total cardiovascular costs, totaling
401/PCI (15), which translates to a saving of nearly $250
illion/year ($401/PCI  622,000 PCIs in 2007). These
ndings support the restricted DES treatment strategy
ndorsed in the United Kingdom and Canada.
One final thought: with baseline event rates now in the
ange of 6% to 7% for TLR and 2% to 3% for ST and
bsolute risk reductions in the range of 2% to 3% and 1% to
%, respectively, we are fast approaching the point of dimin-
shing returns. It is high time for us to acknowledge the
imitations of our success and begin restructuring reimburse-
ent strategies to encourage the judicious, selective, and
vidence-based use of DES in the United States (16).
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